[OT] MNTA: But I will remember MNTA, HES, Vale if and when funds are available.
I just posted an update on MNTA’s 2009-2010 news flow in #msg-39156766.
Unlike most biotech stocks that are awaiting a regulatory decision by the FDA, MNTA cannot be “timed” because FDA reviews of generic drugs do not have formal deadlines. In other words, FDA action on the Lovenox ANDA—the primary driver for MNTA’s share price—could come at any time.